in this area than any other Roche division globally. "Many cancers are curable now, and that is fundamentally due to the working partnership between research and industry," says Miller. The new global pharmaceutical development site is supported by a $7.79-million investment by the Ontario government as part of its plan to attract and retain the best and brightest minds and to support innovation that will spur business growth and create jobs. Ontario was one of several jurisdictions around the world that were considered by Roche decisionmakers for this site. The decision was based on several factors, including Roche Canada's strong clinical research base in this country, the relationship between the company and the scientific and research network, Ontario's well-trained and capable workforce, and a government that places a high strategic priority on life sciences. "It was nice for me to be able to stand up with all these advantages and present a case that made Ontario the best choice," says Miller.